17.06.2010 • News

Symyx Shares Fall after Ending Talks with Possible Buyer

Shares of Symyx Technologies fell 14% Wednesday, a day after the company said it ended talks with Certara, which revoked its offer to buy the scientific research provider for $6.75 a share.

Earlier this month, Symyx agreed to provide information about itself and help Certara, the parent of certain scientific software makers, and its private equity sponsor Vector Capital, with the due diligence process.

Before it received Certara's offer, the company had agreed to merge with Accelrys Inc in a stock deal, which valued Symyx at a little more than $5 a share, or about $175 million. After the merger, each company would own about 50% of the combined entity.

In a regulatory filing on Tuesday, Symyx posted Certara's letter, which said it could offer a substantial cash premium over Accelrys' offer, but not $6.75 a share.

Symyx said it does not have a superior offer under consideration.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

most read